X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (200) 200
humans (183) 183
breast cancer (179) 179
female (172) 172
breast neoplasms - drug therapy (116) 116
middle aged (110) 110
cancer (108) 108
chemotherapy (103) 103
adult (99) 99
breast neoplasms - pathology (88) 88
aged (82) 82
antineoplastic combined chemotherapy protocols - therapeutic use (69) 69
neoadjuvant therapy (64) 64
treatment outcome (63) 63
trastuzumab (59) 59
prognosis (55) 55
survival (54) 54
therapy (53) 53
chemotherapy, adjuvant (46) 46
obstetrics & gynecology (44) 44
breast neoplasms - mortality (42) 42
care and treatment (42) 42
disease-free survival (40) 40
pathological complete response (40) 40
adjuvant treatment (38) 38
research (38) 38
clinical trials (37) 37
cyclophosphamide (35) 35
tumors (34) 34
breast neoplasms - genetics (33) 33
neoadjuvant chemotherapy (33) 33
prospective studies (33) 33
breast neoplasms - metabolism (32) 32
neoplasm staging (32) 32
further section (31) 31
women (31) 31
medicine & public health (30) 30
further section · weitere sektionen (29) 29
analysis (28) 28
paclitaxel (28) 28
cyclophosphamide - administration & dosage (27) 27
docetaxel (27) 27
health aspects (27) 27
taxoids - administration & dosage (27) 27
antineoplastic combined chemotherapy protocols - adverse effects (26) 26
capecitabine (26) 26
doxorubicin (26) 26
drug therapy (26) 26
adjuvant chemotherapy (25) 25
metastasis (25) 25
risk factors (25) 25
trial (25) 25
cancer therapies (24) 24
hematology, oncology and palliative medicine (24) 24
preoperative chemotherapy (24) 24
breast neoplasms - surgery (23) 23
breast neoplasms - therapy (23) 23
erbb-2 protein (23) 23
patients (23) 23
receptor, erbb-2 - metabolism (23) 23
expression (22) 22
germany (22) 22
pregnancy (22) 22
aged, 80 and over (21) 21
antineoplastic agents - therapeutic use (21) 21
epirubicin - administration & dosage (21) 21
immunohistochemistry (21) 21
medical and health sciences (21) 21
medicin och hälsovetenskap (21) 21
surgery (21) 21
abridged index medicus (20) 20
bevacizumab (20) 20
biomarkers (20) 20
breast neoplasms - chemistry (20) 20
lapatinib (20) 20
oncology, experimental (20) 20
randomized controlled trials as topic (20) 20
anthracyclines (19) 19
cancer and oncology (19) 19
cancer och onkologi (19) 19
epidermal growth factor (19) 19
open-label (19) 19
pathology (19) 19
receptor, erbb-2 - analysis (19) 19
clinical medicine (18) 18
klinisk medicin (18) 18
mutation (18) 18
receptors, estrogen - metabolism (18) 18
antineoplastic combined chemotherapy protocols - administration & dosage (17) 17
cancer patients (17) 17
fluorouracil - administration & dosage (17) 17
medicine, general & internal (17) 17
skin and connective tissue diseases (17) 17
young adult (17) 17
breast neoplasms - diagnosis (16) 16
endocrine therapy (16) 16
kaplan-meier estimate (16) 16
lymphocytes (16) 16
receptor, erbb-2 - antagonists & inhibitors (16) 16
tamoxifen (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. e148 - e160
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 135 - 144
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 345 - 356
Journal Article
Journal of cancer research and clinical oncology, ISSN 1432-1335, 2017, Volume 144, Issue 2, pp. 343 - 358
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 3, pp. 209 - 219
In women with hormone-receptor–positive metastatic breast cancer that had progressed after endocrine therapy, palbociclib plus fulvestrant was associated with... 
TARGET | MEDICINE, GENERAL & INTERNAL | THERAPY | FULVESTRANT | CLINICAL-TRIALS | CYCLIN D | RESISTANCE | MUTATIONS | COMBINATION | ESTROGEN-RECEPTOR | 4/6 INHIBITOR PALBOCICLIB | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Estradiol - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Protein Kinase Inhibitors - adverse effects | Receptors, Progesterone - analysis | Pyridines - adverse effects | Aged, 80 and over | Estradiol - adverse effects | Adult | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - therapeutic use | Double-Blind Method | Estradiol - therapeutic use | Biomarkers - analysis | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged | Receptor, ErbB-2 - analysis | Women | Hormone receptors | Care and treatment | Usage | Breast cancer | Diagnosis | Health aspects | Thrombocytopenia | Leukopenia | Endocrine therapy | Fatigue | Metastasis | Cancer therapies | Cyclin-dependent kinase 4 | Fulvestrant | Metastases | Epidermal growth factor | Womens health | S phase | Cell cycle | Neutropenia | G1 phase
Journal Article